| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Division of Cardiology and Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario; 2Division of Cardiology, University Health Network, Toronto, Ontario; and 3Department of Medicine, Montreal Heart Institute, Montreal, Quebec, Canada
Submitted 6 July 2004 ; accepted in final form 10 November 2004
Angiotensin receptor blockers (ARBs) reduce adverse left ventricular (LV) remodeling and improve LV function and survival when started postmyocardial infarction (MI). ARBs also reduce ventricular arrhythmias during ischemia-reperfusion injury when started pre-MI. No information exists regarding their efficacy and safety when started pre-MI and continued peri- and post-MI. We evaluated whether the ARB losartan improves the outcome when started pre-MI and continued peri- and post-MI. Male Wistar rats (n = 502) were treated for 7 days pre-MI with losartan at a high dose (30 mg·kg–1·day–1), progressively increasing dose (3 mg·kg–1·day–1 increased to 10 mg·kg–1·day–1 10 days and 30 mg·kg–1·day–1 20 days post-MI), or no treatment. Ambulatory systolic blood pressure and Holter monitoring were performed for 24 h post-MI. Echocardiography was done 30 days post-MI, and LV remodeling, cardiac hemodynamics, and fetal gene expression were assessed 38 days post-MI. High-dose losartan reduced 24-h post-MI survival compared with the progressive dose and control (21.9% vs. 36.6% and 38.1%, P = 0.033 and P = 0.009, respectively). This was associated with greater hypotension in the high dose and no change in ventricular arrhythmias in all groups. In 24-h post-MI survivors, the progressive dose group had reduced mortality from 24 h to 38 days (8.5% vs. 28.6% for control vs. 38.9% for high dose, P = 0.032 and P = 0.01, respectively). Survivors of both losartan groups demonstrated improved LV remodeling, cardiac hemodynamics, preserved GLUT-4, and reduced cardiac fetal gene expression. Pretreatment with ARBs does not reduce 24-h post-MI ventricular arrhythmias or survival, and high doses increase mortality by causing excessive hypotension. In 24-h post-MI survivors, progressively increasing doses of losartan have multiple beneficial effects, including improved survival.
angiotensin II receptor blockers; heart failure; infarction; remodeling; hypotension
This article has been cited by other articles:
|
|
 |
|
  R. Gopinathannair, A. K. Chaudhary, D. Xing, D. Ely, W. Zheng, and J. B. Martins Angiotensin II effects on ischemic focal ventricular tachycardia are predominantly mediated through myocardial AT2 receptor Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1889 - H1898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Huang, M. Ahmad, J. Tan, and F. H. H. Leenen Chronic central versus systemic blockade of AT1 receptors and cardiac dysfunction in rats post-myocardial infarction Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H968 - H975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Gonzalez, I. M. Seropian, M. L. Krieger, J. Palleiro, M. A. Lopez Verrilli, M. M. Gironacci, S. Cavallero, L. Wilensky, V. H. Tomasi, R. J. Gelpi, et al. Effect of early versus late AT1 receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H375 - H386. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
